A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19

The ARCADIA Trial is a randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with either Type 1 or Type 2 diabetes, hospitalised with COVID-19.

开始日期2020-08-12

申办/合作机构

St George Street Capital Ltd.

NCT05216172

/ Completed临床2期

AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce

AZD1656 in Transplantation with Diabetes tO PromoTe Immune TOleraNce: a single site, placebo-controlled, double-blind randomised clinical trial of AZD1656 in renal transplant patients with Type 2 diabetes

开始日期2019-12-13

申办/合作机构

Queen Mary University of London

[+1]

EUCTR2019-001587-30-GB

/ Unknown status临床2期

AZD1656 in Transplantation with Diabetes tO PromoTe Immune TOleraNce

开始日期2019-07-26

申办/合作机构

Queen Mary University of London

100 项与 AZD-1656 相关的临床结果

登录后查看更多信息

100 项与 AZD-1656 相关的转化医学

登录后查看更多信息

100 项与 AZD-1656 相关的专利（医药）

登录后查看更多信息

项与 AZD-1656 相关的文献（医药）

2025-08-01·INFLAMMOPHARMACOLOGY

Safety profile of glucokinase activator AZD1656: systematic review and meta-analysis of 23 randomised trials in diabetic and healthy volunteers with relevance to immunomodulatory therapy

Review

作者: Abdalla, Mohamed M ; Elsayed, Mohamed M

Abstract:

Glucokinase enzyme plays a pivotal role in various physiological processes such as glucose metabolism, inflammation, and immunity. AZD1656 is a glucokinase activator (GKA) that shows proven efficacy in reducing blood glucose. It also possesses a marked interest in autoimmune diseases due to its immunomodulatory effect. Six databases were searched: PubMed, Scopus, the Cochrane Library, World of Science, ClinicalTrials.gov, and AstrazenecaClinicalTrials.com. This meta-analysis was conducted by following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Twenty-three randomized controlled trials were included in this systematic review, and 19 studies were included in the meta-analysis. There was no significant difference between AZD1656 and placebo. Regarding total non-serious adverse events (a/e), the cumulative relative risk (RR) was 1.09 (95% CI 0.96–1.24, I2 = 30%, p = 0.19). The RR for low doses (< 100 mg), medium doses (≥ 100 and < 200 mg), and high doses (≥ 200 mg) were 1.17 (95% CI 0.98–1.40, I2 = 21%, p = 0.08), 1.19 (95% CI 0.96–1.48, I2 = 49%, p = 0.18), and 1.06 (95% CI 0.78–1.43, I2 = 34%, p = 0.72), respectively. For hypoglycaemic events, the cumulative RR was 2.03 (95% CI 0.94–4.39, I2 = 0%, p = 0.07). The RR for low doses, medium doses, and high doses were 2.59 (95% CI 0.59–11.43, I2 = 0%, p = 0.21), 2.48 (95% CI 0.80–7.72, I2 = 0%, p = 0.16), and 2.17 (95% CI 0.28–16.47, I2 = 0%, p = 0.46), respectively. The cumulative RR for serious a/e was 0.85 (95% CI 0.21–3.48, I2 = 0%). AZD1656 is a well-tolerated, safe glucokinase activator. It has promising potential as an anti-diabetic and immunomodulatory agent, supporting its further investigation in immunomodulatory and inflammatory diseases.

2024-11-01·BIOCHEMICAL PHARMACOLOGY

Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants

Article

作者: Agius, Loranne ; Smith, David M. ; Tiniakos, Dina ; Chachra, Shruti S ; Alshawi, Ahmed ; Ford, Brian E ; Chachra, Shruti S. ; Fairclough, Rebecca J ; Fairclough, Rebecca J. ; Oakley, Fiona ; Smith, David M ; Ford, Brian E.

Glucokinase activators (GKAs) have been developed as blood glucose lowering drugs for type 2 diabetes. Despite good short-term efficacy, several GKAs showed a decline in efficacy chronically during clinical trials. The underlying mechanisms remain incompletely understood. We tested the hypothesis that deficiency in the liver glucokinase regulatory protein (GKRP) as occurs with common human GCKR variants affects chronic GKA efficacy. We used a Gckr-P446L mouse model for the GCKR exonic rs1260326 (P446L) variant and the Gckr-del/wt mouse to model transcriptional deficiency to test for chronic efficacy of the GKA, AZD1656 in GKRP-deficient states. In the Gckr-P446L mouse, the blood glucose lowering efficacy of AZD1656 (3 mg/kg body wt) after 2 weeks was independent of genotype. However after 19 weeks, efficacy was maintained in wild-type but declined in the LL genotype, in conjunction with raised hepatic glucokinase activity and without raised liver lipids. Sustained blood glucose lowering efficacy in wild-type mice was associated with qualitatively similar but more modest changes in the liver transcriptome compared with the P446L genotype, consistent with GKA therapy representing a more modest glucokinase excess than the P446L genotype. Chronic treatment with AZD1656 in the Gckr-del/wt mouse was associated with raised liver triglyceride and hepatocyte microvesicular steatosis. The results show that in mouse models of liver GKRP deficiency in conjunction with functional liver glucokinase excess as occurs in association with common human GCKR variants, GKRP-deficiency predisposes to declining efficacy of the GKA in lowering blood glucose and to GKA induced elevation in liver lipids.

2023-03-01·Aquatic toxicology (Amsterdam, Netherlands)

Are we ready to combat the ecotoxicity of COVID-19 pharmaceuticals? An in silico aquatic risk assessment

Article

作者: Khan, Kabiruddin ; Kar, Supratik ; Roy, Kunal

To fight COVID-19 with uncountable medications and bioproducts throughout the world has taken us to another challenge of ecotoxicity. The indiscriminate usage followed by improper disposal of unused antibacterials, antivirals, antimalarials, immunomodulators, angiotensin II receptor blockers, corticosteroids, anthelmintics, anticoagulants etc. can lead us to an unimaginable ecotoxicity in the long run. A series of studies already identified active pharmaceutical ingredients (APIs) of the mentioned therapeutic classes and their metabolites in aquatic bodies as well as in wastewater treatment plants. Therefore, an initial ecotoxicity assessment of the majorly used pharmaceuticals is utmost requirement of the present time. The present in silico risk assessment study is focused on the aquatic toxicity prediction of 81 pharmaceuticals where 77 are most-used pharmaceuticals for COVID-19 throughout the world based on the literature along with one drug nirmatrelvir [PF-07321332] approved for emergency use by US-FDA and three other molecules under clinical trial. The ecotoxicity of the studied compounds were predicted based on the three aquatic species fish, algae and crustaceans employing the highest quality QSAR models available from the literature as well as using ECOSAR and QSAR Toolbox. To compare the toxicity thresholds, we have also used 4 control pharmaceuticals based on the worldwide occurrence from river, lake, STP, WWTPs, influent and effluent followed by high reported aquatic toxicity over the years as per the literature. Based on the statistical comparison, we have proposed top 3 pharmaceuticals used for the COVID-19 most toxic to the aquatic environment. The study will provide confident predictions of aquatic ecotoxicity data related to abundant use of COVID-19 drugs. The major aim of the study is to fill up the aquatic ecotoxicity data gap of major medications used for COVID-19.

项与 AZD-1656 相关的新闻（医药）

2026-04-17

·药出海

二型糖尿病药物研发趋势及相关靶点解析

2025年国际糖尿病联盟（IDF）发布的数据显示，2024年，全球20~79岁的糖尿病患者达5.89亿人，预计2050年将达到8.53亿。而2型糖尿病（T2DM）占所有糖尿病病例的90%~95%，其不是单一的血糖升高疾病，而是一种累及全身的代谢综合征，因此治疗理念已从“单一降糖”逐渐转变成血糖、血压、血脂、体重等控制的“多器官代谢调节”综合管理模式。目前已有多类成熟药物应用于2型糖尿病（T2DM）的临床治疗，但随着对疾病发病机制研究的不断深入，以及临床对个性化治疗、多靶点获益、长期安全性的需求持续提升，现有药物已难以完全满足复杂的临床场景。理想的药物或许应具备持久的降糖效果（优于现有药物）、低血糖风险极低、有助于体重控制，并有望带来更多的心肾等额外获益（尤其是针对相关并发症）。这类药物可能具有独特且互补的作用机制，适合于联合治疗，和/或适用于现有药物在2型糖尿病（T2DM）中疗效不佳的临床场景，如合并肥胖、动脉粥样硬化、心血管疾病、心力衰竭、慢性肾病等。因此，近年来，2 型糖尿病（T2DM）药物研发从 “单一降糖” 全面转向多器官代谢调节、心肾保护、强效减重、便捷给药、精准干预的综合治疗时代，多个药物获批上市或进入临床关键阶段，有望成为未来2 型糖尿病（T2DM）治疗的新方案。 GIPR/GCGR/GLP 开启降糖&减重的多靶点研发赛道肠促胰素通路是当前全球 2 型糖尿病与肥胖治疗的核心研发赛道，此类靶点通过靶向肠促胰素/升糖激素受体，实现降糖、减重、心肾保护等多重获益。 GIPR（葡萄糖依赖性促胰岛素多肽受体）与 GLP-1R 同属人体内两大核心肠促胰素受体，单靶点 GLP-1R 激动剂已成为 2 型糖尿病一线治疗药物，而GIPR 与 GLP-1R 双靶点激动可产生显著的协同效应。 GCGR（胰高血糖素受体）与胰岛素共同维持正常血糖水平，在糖代谢稳态方面起着重要作用。GLP-1R/GCGR 双靶点激动剂可同时实现 GLP-1R 的降糖、减重获益，与 GCGR 激动带来的能量消耗增加、肝脏糖脂代谢改善的协同效应，减重、调脂效果显著优于单靶点 GLP-1RA，同时兼顾空腹与餐后血糖调控。研发进展与竞争格局全球已有 GIPR/GLP-1R 或GCCR/GLP-1R双靶点激动剂获批上市，多款双或多靶点药物进入临床关键阶段，核心品种如下：药品名称核心研发企业靶点组合最高研发阶段（2型糖尿病）核心进展替尔泊肽（Tirzepatide）礼来 GIPR/GLP-1R 双激动剂全球获批上市全球首个获批的 GIPR/GLP-1R 双激动剂，III 期临床显示可降低 HbA1c 最高达 2.4%，减重最高达 22.5%，疗效显著优于单靶点 GLP-1RA 玛仕度肽（IBI362）信达生物 GCGR/GLP-1R 双激动剂中国获批上市全球首个获批的GCG/GLP-1双靶点受体激动剂瑞替鲁肽（Retatrutide）礼来 GIPR/GLP-1R/GCGR 三激动剂临床 III 期全球进展最快的三靶点激动剂，首个III期结果公布，在40周的治疗期内，实现了高达2.0%的糖化血红蛋白（HbA1c）显著降幅，减重比例为16.8%（平均16.6 kg） UBT251 联邦制药&诺和诺德 GLP-1R/GIPR/GCGR 三激动剂临床 II 期中国2型糖尿病患者的II期临床研究中，用药24周后患者平均糖化血红蛋白（HbA1c）降幅最高达2.16%，且平均体重降幅最高达9.8% Efinopegdutide 默沙东 GLP-1R/GCGR 双激动剂临床 II 期针对 2 型糖尿病合并 NASH 的适应症完成 II 期临床，显示出明确的降糖、减重、保肝获益 HDM1005 中美华东 GLP-1R/GCGR 双激动剂临床III 期数据来源：药出海根据公开信息整理 GKA 靶向 “血糖传感器” 葡萄糖激酶（GK）是机体葡萄糖稳态的核心 “传感器”，主要在胰岛 β 细胞、肝脏细胞、肠道内分泌细胞中表达，可精准感知血糖浓度变化。葡萄糖激酶激活剂（GKA）是目前唯一直接靶向 “血糖传感器” 的降糖药物，从根源上修复 2 型糖尿病患者的血糖调控能力，而非单纯降糖，兼具明确的胰岛 β 细胞功能保护获益。研发进展与竞争格局全球针对 2 型糖尿病适应症的 GKA 已有十多款进入临床及以上阶段，其中多格列艾汀（dorzagliatin）由华领医药开发，已于 2022 年在中国获批上市，是全球首个获批上市的 GKA 类药物。其余核心在研品种如下：药品名称核心研发企业适应症最高研发阶段多格列艾汀 dorzagliatin 华领医药罗氏 2型糖尿病神经退行性疾病 2022年批准上市 PB-201 辉瑞 2型糖尿病1型糖尿病临床 III期卡迪格列汀（cadiseglati） Viv Therapeutics 2型糖尿病1型糖尿病癌症临床 III 期 AMG-151 Array BioPharma 2型糖尿病临床 II 期 AZD-1656 阿斯利康 2型糖尿病1型糖尿病临床 II 期 LY-2599506 Osi Pharmaceutical 礼来 2型糖尿病临床 II 期 MK-0941 默沙东 2型糖尿病肾功能不全临床 II 期 PF-04991532 辉瑞 2型糖尿病临床 II 期 TMG-123 帝人制药 2型糖尿病临床 II 期 AZD-5658 阿斯利康 2型糖尿病临床 I期 AZD-6370 阿斯利康 2型糖尿病临床 I期数据来源：药智网 AMPK 能量代谢调控的核心枢纽 AMP 活化蛋白激酶（AMPK）是机体能量稳态的核心调节因子，被称为 “细胞能量传感器”。在能量匮乏时，AMPK抑制脂肪酸合成、胆固醇合成及糖异生等消耗ATP的代谢途径，同时促进脂肪酸氧化，是代谢性疾病治疗的 “明星靶点”。研发进展与竞争格局 AMPK 是目前 2 型糖尿病领域研发最成熟的靶点之一，全球已有多个品种进入临床关键阶段，其中多个品种获批上市，代表药物是二甲双胍。 FBP1 抑制糖异生的口服降糖策略果糖 - 1,6 - 二磷酸酶 1（FBP1）是肝脏糖异生通路的关键限速酶，直接调控肝脏内源性葡萄糖的生成与输出。2 型糖尿病患者体内 FBP1 活性异常升高，是导致空腹高血糖、肝源性胰岛素抵抗的重要原因。研发进展与竞争格局全球针对 2 型糖尿病适应症的 FBP1 抑制剂共有多款在研，核心品种进展如下：药品名称核心研发企业适应症最高研发阶段 VK0612 Ligand PharmaceuticalViking Therapeutics 2型糖尿病临床 II 期马格列奈（managlinat dialanetil）第一三共制药 2型糖尿病临床 II 期 Cpd118 中国医学科学院药物研究所 2型糖尿病临床前数据来源：药智网 VK0612作为一种口服FBP1抑制剂，II 期临床数据显示，其可显著降低血糖控制不佳的 2 型糖尿病患者的空腹与餐后血糖，降糖效果呈剂量依赖性，且整体安全性与耐受性良好。 GPR119 双重机制调控血糖与体重 G 蛋白偶联受体 119（GPR119）主要在胰岛 β 细胞和肠道内分泌细胞（L 细胞、K 细胞）中高表达。激动 GPR119 可提升细胞内 cAMP 水平，一方面直接促进胰岛 β 细胞葡萄糖依赖性的胰岛素分泌，另一方面通过刺激肠道内分泌细胞分泌 GLP-1、GIP 等肠促胰素，间接调控胰岛素释放，同时还能发挥抑制食欲、减轻体重的额外获益，实现降糖与减重的双重作用。研发进展与竞争格局针对 2 型糖尿病适应症，全球已有多款 GPR119 激动剂进入临床试验阶段，目前暂无药物获批上市，核心在研品种如下：药品名称核心研发企业适应症最高研发阶段 DA-1241 MetaVia Inc、东亚ST株式会社 2型糖尿病、非酒精性脂肪性肝炎临床II期 GSK-1292263 葛兰素史克 2型糖尿病、低血脂症、高血脂症临床II期 LEZ-763 诺华 2型糖尿病临床II期 MBX-2982 CymaBay Therapeutics、赛诺菲 2型糖尿病临床II期 PSN-821 Prosidion Ltd、阿斯利康 2型糖尿病临床II期呋格列哌（fruglipel）第一三共制药 2型糖尿病临床II期 APD-597 Arena Pharmaceuticals、强生 2型糖尿病临床I期 BMS-903452 百时美施贵宝糖尿病临床I期数据来源：药智网 THR-β 线粒体代谢调节新思路甲状腺激素受体（THR）分为 α、β 两个核心亚型，其中THR-β 可同时改善 2 型糖尿病患者最常见的血脂异常、NAFLD 等合并症，直击代谢综合征的核心病理机制，尤其适合合并多种代谢紊乱的 2 型糖尿病患者。研发进展与竞争格局 TRC150094 是一款靶向 THR 通路的新型线粒体调节剂，可通过选择性调控 THR-β 功能改善 2 型糖尿病患者的糖脂代谢紊乱。目前 TRC150094 针对 2 型糖尿病合并高脂血症的多剂量II期研究显示，在标准治疗方案基础上联用（25 mg、50 mg、75 mg）治疗24周的效果，结果显示患者空腹血糖（FPG）、糖化血红蛋白（HbA1c）、空腹胰岛素水平及胰岛素抵抗指数（HOMA-IR）均显著改善。 DGAT2 从脂肪合成源头调控代谢二酰甘油酰基转移酶（DGAT）是催化体内三酰甘油（TAG）合成的关键限速酶，分为 DGAT1 和 DGAT2 两个亚型。其中DGAT2 主要在肝脏、胰岛、脂肪组织中高表达，是肝脏甘油三酯合成的核心亚型。2 型糖尿病患者体内 DGAT2 活性过高，会导致甘油三酯过度沉积，引发胰岛β细胞脂毒性损伤、功能障碍，同时加重肝脏胰岛素抵抗与糖异生异常。 DGAT2 抑制剂可改善胰岛β细胞功能损伤与胰岛素抵抗，对 2 型糖尿病常见的合并症 NASH 具有较明确的效果，实现 “糖脂肝” 同调。研发进展与竞争格局 IONIS-DGAT2Rx是一款靶向 DGAT2 的反义寡核苷酸药物，其针对 2 型糖尿病的适应症已完成临床 I 期研究。缓激肽通路（KLK1 - 缓激肽轴）缓激肽是体内重要的血管活性肽，可通过激活缓激肽 B2 受体，促进外周组织葡萄糖摄取，提升全身胰岛素敏感性，同时改善微循环、减轻胰岛氧化应激损伤，发挥降糖与胰岛保护双重作用。研发进展与竞争格局 DM199 （重组人组织激肽释放酶 1（rhKLK1））针对 2 型糖尿病的适应症已完成 II 期临床试验。 ANGPTL3 降脂兼顾血糖调控的新靶点血管生成素样蛋白 3（ANGPTL3）主要在肝脏中表达，是调控脂质代谢与糖代谢的关键蛋白。其可抑制脂蛋白脂肪酶活性，调控甘油三酯循环，同时通过升高游离脂肪酸水平加速胰岛素抵抗，实现糖脂同调。研发进展与竞争格局瓦帕诺生（vupanorsen）是一款靶向 ANGPTL3 的反义寡核苷酸药物，其 II 期临床研究显示，在合并高甘油三酯血症与 2 型糖尿病的 NAFLD 患者中，瓦帕诺生可显著降低患者甘油三酯水平，同时改善胰岛素抵抗与血糖控制，缓解肝脏脂肪变性。 LYN 酪氨酸激酶非PPARγ途径的胰岛素增敏剂 Lyn 酪氨酸激酶是 Src 家族非受体酪氨酸激酶的核心成员，是胰岛素信号通路的关键调控分子。其可通过磷酸化胰岛素受体（IR）与胰岛素受体底物（IRS），增强胰岛素信号通路的传导，显著改善肝脏、肌肉、脂肪组织的外周胰岛素抵抗，提升机体对胰岛素的敏感性，进而降低血糖。研发进展与竞争格局 Tolimidone（MLR-1023）是一款高选择性 Lyn 酪氨酸激酶激动剂，通过非PPARγ途径发挥胰岛素增敏作用，其 II 期临床研究显示，对于口服降糖药血糖控制不佳的 2 型糖尿病患者，MLR-1023 可显著降低餐后血糖曲线下面积（PPG AUC）与糖化血红蛋白水平，改善胰岛素抵抗，且安全性与耐受性良好。 / 其他值得关注的靶点/方向除上述T2DM直接靶点，以及多器官代谢调节的靶点外，全球还有多个具备临床价值的 2 型糖尿病药物正在快速推进研发，覆盖口服降糖药升级、免疫代谢调控、内分泌代谢、中枢能量调控等多个前沿方向，涉及靶点/方向包括胰淀素类似物、FGF21、GDF15、MC4R、SGLT1/2 、NLRP3/IL-1β等。代表性进展如下：靶点/方向核心机制核心品种及进展（2型糖尿病适应症）胰淀素类似物延缓胃排空，抑制餐后胰高血糖素 BGM1812（临床前） FGF21类似物/ 激动剂改善胰岛素抵抗与脂质代谢 HEC88473（GLP-1/FGF21双激动剂，II期）、Efruxifermin（FGF21类似物）II期、 GDF15受体激动剂作用于后脑抑制食欲，独立于GLP-1 主要作为四靶点激动剂组成部分（临床前） MC4R 激动剂激活下丘脑摄食中枢，抑制食欲、增加能量消耗，通过强效减重改善胰岛素抵抗针对 2 型糖尿病合并肥胖的适应症进入全球 III 期临床 SGLT1/2 双靶点抑制剂同时阻断肾脏与肠道葡萄糖重吸收，完整保留 SGLT2 抑制剂的心肾保护获益礼来索格列净已在欧盟获批 1 型、2 型糖尿病适应症；国内恒瑞医药、华领医药等进入 II/III 期临床 NLRP3/IL-1β抑制剂阻断代谢性炎症通路，减轻胰岛 β 细胞凋亡，改善全身胰岛素抵抗卡那单抗 II期临床总结总体而言，糖尿病管理模式已从传统的“单一降糖”逐步迈向 “多机制、多获益、全病程管理” 的全新阶段，现有的和研发中的T2DM治疗药物，已覆盖肠促胰素调控、胰岛功能保护、肝脏糖代谢、脂代谢紊乱、代谢性炎症等 2 型糖尿病全链条病理机制，可同时实现降糖、调脂、减重、器官保护等多重获益，临床中应根据不同患者情况，考虑当前HbA1c、并发症等因素，合理选择降糖药物，提高患者依从性以及治疗成功率。特别声明以上内容仅代表作者本人的观点或立场，不代表药出海的观点或立场。因作者水平有限，加之信息更新太快，资料搜集难度较大，本文难免存在不足和疏漏之处，恳请广大读者、专家学者不吝赐教，批评指正。如因作品内容、版权或其他问题需要可联系我们。参考资料 [1]DeMarsilis A, Reddy N, Boutari C, et al. Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism. 2022 Dec;137:155332. [2]Overton HA, Fyfe MC, Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol. 2008;153 (Suppl 1):S76–81. [3]Joshi D, Gj P, Ghosh S, et al. TRC150094, a novel mitochondrial modulator, reduces cardio-metabolic risk as an add-on treatment: a phase-2, 24-week, multi-center, randomized, double-blind,clinical trial. Diabetes Metab Syndr Obes. 2022;15:615–31. [4]Kolodka T, Charles ML, Raghavan A, et al. Preclinical characterization of recombinant human tissue kallikrein-1 as a novel treatment for type 2 diabetes mellitus. PLoS One. 2014;9(8):e103981. [5]Wentworth JM, Colman PG, Zafgen Study Group. The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2020;22:1215–9. [6]Christopoulou E, Elisaf M, Filippatos T. Effects of angiopoietin-like 3 on triglyceride regulation, glucose homeostasis, and diabetes. Dis Markers. 2019;2019:6578327. [7]Steinberg GR, Carling D. AMP-activated protein kinase: the current landscape for drug development. Nat Rev Drug Discov. 2019;18:527–51. [8]Toulis KA, Nirantharakumar K, Pourzitaki C, et al. Glucokinase activators for type 2 diabetes: challenges and future developments. Drugs. 2020;80:467–75. [9] Lee MK, Kim SG, Watkins E, et al. A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus. J Diabetes Complications. 2020;34:107555. 免责声明本公众号所发布的文章，旨在为读者提供一般性的知识、观点和信息。尽管我们努力确保文章内容的准确性与可靠性，但由于知识的不断更新以及实际情况的复杂性，文章内容可能存在一定的时效性与局限性，并不构成专业建议。公众号文章中的观点与评论仅代表作者个人立场，并不一定反映药出海运营主体的观点。我们尊重不同的观点与意见，欢迎读者理性探讨，但对于因文章观点引发的任何争议，本公众号不承担法律责任。 (引用和参考资料如有侵权请及时联系，我们将在24小时内删除处理。) 药品出海合作：Lim 17302664199 器械出海合作：李经理 18682296225 研发合作：李博士：lihuiming@kexing.com 投稿/转载/媒体合作： Zane 15118150289

2026-04-16

·GlobeNewswire-Health Care

CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today provides a strategic update outlining its positioning as a multi-pathway value creation business spanning a pharmaceutical asset portfolio, proprietary solid-form intellectual property and artificial intelligence-driven indication discovery. The Company believes it is uniquely positioned through a combination of high-quality clinical assets, proprietary chemistry, and advanced data-driven capabilities to generate long-term shareholder value through a capital-efficient, out-licensing model. CDT continues to evaluate and advance its portfolio of assets licensed from AstraZeneca, including AZD1656, AZD5658 and AZD5904, which benefit from extensive clinical validation and established safety profiles, through combination therapies and novel indications. These assets are a strong foundation for partnership, supported by CDT’s ongoing solid-form and cocrystal innovation programs designed to enhance physicochemical properties and extend patent life. In parallel, the Company continues to expand and refine its portfolio of solid-form intellectual property, developing improved versions of existing pharmaceutical compounds. These assets are positioned for commercialization with disease-focused pharmaceutical companies or capital partners seeking to advance development into later-stage clinical programs. A core component of CDT’s strategy is its integration with Sarborg Limited, of which CDT owns 20%. Sarborg’s proprietary Signature Intelligence enables the identification of high-probability disease indications for specific compounds through large-scale analysis of biological and chemical signatures in minutes, rather than years. This allows CDT to generate curated, data-driven packages for potential partners, combining solid-form IP with AI-informed indication selection to enhance both scientific validity and commercial attractiveness. This integrated approach enables CDT to efficiently identify, enhance, and position assets for licensing, while minimizing exposure to the cost and risk associated with late-stage clinical development. The Company believes this model provides multiple avenues for value realization, including upfront payments, milestone revenues, and long-term royalties. In addition, CDT’s ownership in Sarborg provides shareholders with unique exposure to a private, agentic AI signature intelligence business operating across multiple sectors. As Sarborg is not publicly listed, CDT represents a singular opportunity for public market investors to gain indirect exposure to this emerging technology. An updated corporate presentation outlining CDT’s strategy and value creation framework can be accessed here: https://www.cdtequity.com/investors/corporate-presentation/ “CDT is now positioned to identify, enhance and commercialize high-value pharmaceutical assets with speed and precision,” said Dr. Andrew Regan, Chief Executive Officer. “By combining clinically validated assets from AstraZeneca, a growing portfolio of solid-form intellectual property, and AI-driven indication discovery through our stake in Sarborg, we expect to generate high-value partnership and licensing opportunities. We are already seeing clear signals that combination therapies are becoming an increasingly important part of the future of drug development, alongside a broader shift across the sector toward faster, data-driven decision-making and more targeted development strategies. We believe this trend will continue to accelerate, fundamentally changing how pharmaceutical assets are selected and repurposed, and CDT is well positioned to capitalise on this shift.” Cautionary Statement Regarding Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT's future results of operations and financial position, CDT's business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations. Investors CDT Equity Inc. Info@cdtequity.com

2026-03-04

·GlobeNewswire-Health Care

CDT Positions for Transformational Growth

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 04, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) advances multiple initiatives designed to enhance shareholder value and expand its strategic footprint. The Company continues to actively develop and expand its pharmaceutical asset portfolio, including solid-form and cocrystal development programs, alongside its licensed clinical assets AZD1656, AZD5658 and AZD5904 under its agreement with AstraZeneca. CDT remains engaged in ongoing evaluation and out-licensing discussions and continues to assess pathways to maximize the commercial and strategic potential of these assets. The Company believes this diversified asset base provides several avenues through which value may be realized. In addition, CDT recently completed its strategic acquisition of a 20% equity stake in Sarborg for an initial consideration of $115 million, providing shareholders with direct participation in a growing agentic AI signature intelligence business whose activities extend beyond pharmaceuticals into additional sectors, including bacteria and agrochemicals. The consideration was satisfied through the issuance of common stock and pre-funded warrants, reinforcing its balance sheet. CDT believes the transaction enhances its overall asset position and broadens its exposure to scalable, data-driven opportunity sets across multiple industries. The Company believes it is in a strong position to evaluate opportunities that could be materially transformative to its balance sheet and market capitalization. CDT continues to assess strategic transactions, partnerships and corporate initiatives that may enhance its financial position and long-term growth profile. Subject to customary approvals, the Company also expects to retain access to capital markets tools that may further strengthen its financial flexibility and strategic optionality. “We are focused on pursuing transformational opportunities that enhance shareholder value,” said Dr. Andrew Regan, Chief Executive of CDT. “Through our investment in Sarborg, continued development of our pharmaceutical portfolio, and disciplined evaluation of strategic transactions, we believe CDT has multiple pathways to drive meaningful long-term growth.” CDT also continues to evaluate capital markets initiatives that may further strengthen its financial flexibility and support the execution of its strategic objectives. For further information or to discuss potential strategic opportunities, please contact the Company at info@cdtequity.com. About CDT Equity Inc. CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation. Cautionary Statement Regarding Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT's future results of operations and financial position, CDT's business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations. InvestorsCDT Equity Inc. Info@cdtequity.com

并购

100 项与 AZD-1656 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14810

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床2期	捷克	St George Street Capital Ltd.	2020-08-12
新型冠状病毒感染	临床2期	罗马尼亚	St George Street Capital Ltd.	2020-08-12
新型冠状病毒感染	临床2期	英国	St George Street Capital Ltd.	2020-08-12
糖尿病	临床2期	捷克	St George Street Capital Ltd.	2020-08-12
糖尿病	临床2期	罗马尼亚	St George Street Capital Ltd.	2020-08-12
糖尿病	临床2期	英国	St George Street Capital Ltd.	2020-08-12
终末期肾脏病	临床2期	英国	AstraZeneca PLC	2019-12-13
移植并发症	临床2期	英国	AstraZeneca PLC	2019-12-13
2型糖尿病	临床2期	美国	AstraZeneca PLC	2009-01-01
抗中性粒细胞胞质抗体相关性血管炎	临床2期	美国	CDT Equity, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04516759 (ARCADIA, Pubmed) 人工标引	临床2期	新型冠状病毒感染 \| 糖尿病	153	AZD-1656	鬱憲衊鏇繭夢襯獵製築(鬱鏇鏇網繭艱築糧餘憲) = 繭餘顧襯餘憲獵襯鏇願壓壓鹹淵壓簾網鹹顧鹽 (艱選積遞獵鑰製淵襯醖 ) 更多	不佳	2022-08-18
				Placebo	鬱憲衊鏇繭夢襯獵製築(鬱鏇鏇網繭艱築糧餘憲) = 壓繭襯蓋衊鹽蓋齋鏇廠壓壓鹹淵壓簾網鹹顧鹽 (艱選積遞獵鑰製淵襯醖 ) 更多
NCT04516759 (ARCADIA, CTgov)	临床2期	新型冠状病毒感染 \| 糖尿病	170	AZD1656 (AZD1656 (Plus Usual Hospital Care))	鹹艱衊膚網餘築製築廠 = 繭艱衊積鬱淵淵艱獵鹽範願淵觸願選夢築繭製 (網構觸鬱夢鏇簾襯獵壓, 夢衊鑰齋築衊鏇糧衊窪 ~ 鹹餘廠齋襯遞齋廠簾願) 更多	-	2022-04-25
				Placebo (Matched Placebo (Plus Usual Hospital Care))	鹹艱衊膚網餘築製築廠 = 鑰鬱繭襯醖鹹簾觸製艱範願淵觸願選夢築繭製 (網構觸鬱夢鏇簾襯獵壓, 遞糧衊繭構顧鑰鹽衊糧 ~ 糧構鏇獵憲壓廠鏇獵鬱) 更多
NCT01152385 (Pubmed \| Diabetes Obes Metab)	临床2期	2型糖尿病	224	AZD1656 40-200 mg	夢觸鏇顧鏇遞繭夢艱繭(齋窪遞鬱壓願膚繭廠餘) = 廠憲獵選獵廠鏇壓獵憲衊繭壓觸範觸製築遞鏇 (鑰餘醖繭獵廠夢餘廠築, ( ~ 0.65, 0.20))	-	2013-10-01
				Placebo	夢觸鏇顧鏇遞繭夢艱繭(齋窪遞鬱壓願膚繭廠餘) = 鹹選齋鹹憲築鹽襯夢選衊繭壓觸範觸製築遞鏇 (鑰餘醖繭獵廠夢餘廠築 )
NCT01020123 (CTgov)	临床2期	2型糖尿病	530	AZD1656+metformin (Higher Dose)	艱願築築網獵夢壓觸襯(顧積齋積醖鹽構築齋窪) = 獵製積遞壓鹹廠餘壓範簾蓋憲餘艱糧壓築鹽衊 (淵糧鬱憲觸網範壓膚簾, 衊鑰選鬱襯鏇構觸艱築 ~ 選餘淵遞顧簾顧蓋鬱廠) 更多	-	2012-11-26
				AZD1656+metformin (Lower Dose)	艱願築築網獵夢壓觸襯(顧積齋積醖鹽構築齋窪) = 膚範遞繭憲顧夢淵膚憲簾蓋憲餘艱糧壓築鹽衊 (淵糧鬱憲觸網範壓膚簾, 範醖簾積鏇獵餘窪簾繭 ~ 餘鑰鏇簾選壓繭醖範製) 更多
NCT00856908 (CTgov)	临床2期	2型糖尿病	20	AZD1656 (Experimental)	鏇顧遞齋鑰簾膚夢夢窪(顧蓋網餘衊膚積構繭夢) = 襯構鏇製觸蓋鏇鏇艱簾願鏇繭衊憲淵艱窪選鹹 (顧壓醖選顧鹽選網鑰齋, 8.5) 更多	-	2012-11-26
				placebo (Placebo Comparator)	鏇顧遞齋鑰簾膚夢夢窪(顧蓋網餘衊膚積構繭夢) = 顧網廠窪簾鬱遞積醖鹹願鏇繭衊憲淵艱窪選鹹 (顧壓醖選顧鹽選網鑰齋, 6.4) 更多